Ryosuke Umino

HBP surgeon, National Cancer Center Hospital, Japan.
🇯🇵🏉🍷🏃

[Wungki Park, MD MS @CentralParkWMD]

1/n

Daraxonrasib (RMC-6236), the first-in-human oral 💊RAS(ON) multi-selective tri-complex inhibitor, in previously treated RAS-mutated pancreatic cancer phase I/II study is now published in the New England Journal of Medicine @NEJM

A novel💡 way to shut down ⚔️RAS, one of the most important oncogenic drivers in cancer that had long been considered “undruggable.”

🔗https://t.co/ptfNVcxrb4

Shout out to Brian Wolpin, @CentralParkWMD @GarridoLagunaMD @AlexSpiraMDPhD @salmanpunekar @MeredithPelster @bherzbergmd Nilo Azad Aparna Hegde @DavidHongMD and the whole team who dedicated to this study. @EileenMOReilly

#HBP #HumansBeyondPatients

[NEJM @NEJM]

Channing J. Der, PhD, and Jen Jen Yeh, MD, describe the scientific foundations of a phase 1–2 study of daraxonrasib to treat metastatic pancreatic ductal adenocarcinomas.

Learn about the science behind the study in the editorial “Advances in RAS Therapeutics for Pancreatic Cancer,” from the University of North Carolina at Chapel Hill (@unc): https://t.co/rDDjGqRJtL

[Ryosuke Umino @RyosukeUmi]

@Markiian_NZ I hope we can meet sometime. You’re always welcome back.

[Ryosuke Umino @RyosukeUmi]

We were honored to host @Markiian_NZ from Ukraine as an observer fellow🎉 He was highly motivated and formed close bonds with many of us. Thank you, Dr Mark!

[Annals of Surgical Oncology @AnnSurgOncol]

January Issue: Editorial: Defining the Role of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) @DrZacharyJBrown

https://t.co/i6UqZDTQMq

@SchultzKurt
@SyedAAhmad5
@SocSurgOnc

[Ryosuke Umino @RyosukeUmi]

Our newly published paper!
"Reappraisal of the Clinical Utility of Hi-Cut Pancreaticoduodenectomy for Widespread Distal Cholangiocarcinoma: A Less Invasive Alternative to Hepatopancreatoduodenectomy"

@AnnSurgOncol

https://t.co/e7PP7wRkTz

[Ryosuke Umino @RyosukeUmi]

So educational and delicious!

[波多野悦朗 @EtsuroHatano]

https://t.co/xW9cQyAyki

[Stefano Crippa @StefanoCrippa6]

🇮🇹CASSANDRA TRIAL🇮🇹

Phase 3 RCT: Neoadjuvant PAXG vs mFOLFIRINOX in resectable/BR #PDAC

💥PAXG shows:
✅⬆️EFS
✅⬆️Path response
✅Suggestion of ⬆️OS
✅Same toxicity

PAXG superior to mFOLFIRINOX?

@IHPBA @EurPancClub @EAHPBA @OncoAlert @OfficialPCA @Oncoinfo_it @hpb_so

[Annals of Surgical Oncology @AnnSurgOncol]

Featured: Molecular KRAS ctDNA Predicts Metastases and Survival in #PancreaticCancer : A Prospective Cohort Study. @RAR__MD @3amrogram @TELL_Starlinger

https://t.co/0ffYH2Y3D6

@GilbertZMurimwa
@SyedAAhmad5

[Annals of Surgery @AnnalsofSurgery]

The penultimate #AmerSurg25 presentation by @brady_campbell @jhatjhmi1: "Mutational Status of Driver Genes in Patients with Resected Pancreatic Ductal Adenocarcinoma Is Associated with Pathological Characteristics and Overall Survival"

[Ryosuke Umino @RyosukeUmi]

Honored to present @PancreasClub and @DDWMeeting -and San Diego was absolutely amazing!!